{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:14:30Z","timestamp":1769534070383,"version":"3.49.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302803"],"award-info":[{"award-number":["82302803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gallbladder adenosquamous carcinoma (GBASC) is an uncommon, highly aggressive neoplasm characterized by the coexistence of both glandular and squamous cells. Representing fewer than 5% of gallbladder malignancies, GBASC demonstrates a more aggressive behavior and has poorer prognosis, posing considerable challenges for early diagnosis and effective management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We present a case of GBASC in a 52-year-old woman who achieved long-term tumor-free survival by surgery, as well as targeted and immunotherapy after the operation. Targeted gene sequencing and bioinformatics analysis tools, including STRING, GeneMANIA, Metascape, TRRUST, Sangerbox, and cBioPortal, were used to analyze the biological functions and features of the mutated genes in GBASC. A total of 16 mutations (\n                      <jats:italic>NF2<\/jats:italic>\n                      ,\n                      <jats:italic>EGFR<\/jats:italic>\n                      ,\n                      <jats:italic>EPHA2<\/jats:italic>\n                      ,\n                      <jats:italic>CDK6<\/jats:italic>\n                      ,\n                      <jats:italic>LATS2<\/jats:italic>\n                      ,\n                      <jats:italic>NBN<\/jats:italic>\n                      ,\n                      <jats:italic>CUL3<\/jats:italic>\n                      ,\n                      <jats:italic>FRAS1<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>KMT2A<\/jats:italic>\n                      ,\n                      <jats:italic>EXT1<\/jats:italic>\n                      ,\n                      <jats:italic>SMARCA1<\/jats:italic>\n                      ,\n                      <jats:italic>RECQL4<\/jats:italic>\n                      ,\n                      <jats:italic>KMT2D<\/jats:italic>\n                      ,\n                      <jats:italic>POLQ<\/jats:italic>\n                      , and\n                      <jats:italic>CTNND2<\/jats:italic>\n                      ) were identified, and the tumor mutation burden was determined to be 5.73 mut\/Mb via targeted gene sequencing. The protein\u2013protein interaction network highlighted robust connections among the 16 mutated genes. Functional enrichment via Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses pinpointed tumor-associated signaling cascades. Moreover, based on bioinformatics analysis, the key points at the treatment duration of this patient were discussed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comparative analyses with other gallbladder carcinoma subtypes revealed GBASC to have distinct clinical phenotypes, molecular alterations, functional characteristics, and enriched signaling pathways. Moreover, there is an urgent need for standardized treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1697015","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:20:07Z","timestamp":1769412007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted gene sequencing and bioinformatics analysis of a patient with gallbladder adenosquamous carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yangjun","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Shulan Hangzhou Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhitao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Shulan Hangzhou Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, Shulan Hangzhou Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-020-04729-w","article-title":"Comparative outcomes of adenosquamous carcinoma of the gallbladder: an analysis of the national cancer database","volume":"25","author":"Murimwa","year":"2021","journal-title":"J Gastrointest Surg"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.110015","article-title":"Characterization and clinical outcomes of rare biliary adenosquamous carcinoma","volume":"51","author":"Ruffat","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24065","article-title":"Squamous\/adenosquamous carcinoma of the gallbladder: Analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma","volume":"112","author":"Song","year":"2015","journal-title":"J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9693-2","article-title":"Squamous cell\/adenosquamous carcinomas and adenocarcinomas of the gallbladder: an immunohistochemistry study of prognostic markers","volume":"20","author":"Li","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2025.02.004","article-title":"Adenosquamous carcinoma of the gallbladder: a Bi-institutional experience in managing this rare entity","author":"Varty","year":"2025","journal-title":"HPB (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116275","article-title":"Comparison of clinicopathological characteristics and long-term survival between patients with gallbladder adenosquamous carcinoma and pure gallbladder adenocarcinoma after curative-intent surgery: a single-center experience in China and a meta-analysis","volume":"13","author":"Lv","year":"2023","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","article-title":"Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky311","article-title":"GeneMANIA update 2018","volume":"46","author":"Franz","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1013","article-title":"TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions","volume":"46","author":"Han","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316039","article-title":"Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis","volume":"68","author":"Li","year":"2019","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040733","article-title":"Molecular classification and tumor microenvironment characterization of gallbladder cancer by comprehensive genomic and transcriptomic analysis","volume":"13","author":"Ebata","year":"2021","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153806","article-title":"Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved","volume":"232","author":"Mishra","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31850","article-title":"Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations","volume":"125","author":"Narayan","year":"2019","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1721180","article-title":"Genomic landscape and targeted treatment of gallbladder cancer: results of a first ongoing prospective study","volume":"9","author":"Patel","year":"2020","journal-title":"South Asian J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1002\/cti2.1483","article-title":"A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer","volume":"13","author":"Zhou","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e23986","DOI":"10.1002\/jcla.23986","article-title":"Combination of anlotinib and gemcitabine promotes the G0\/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma","volume":"35","author":"Fan","year":"2021","journal-title":"Vitro J Clin Lab Anal"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5632744","article-title":"Anlotinib inhibits tumor angiogenesis and promotes the anticancer effect of radiotherapy on esophageal cancer through inhibiting ephA2","volume":"2022","author":"Gu","year":"2022","journal-title":"J Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1453895","article-title":"Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features","volume":"14","author":"Duan","year":"2024","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-024-01957-3","article-title":"Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial","volume":"9","author":"Han","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001546","article-title":"Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature","volume":"35","author":"Qiu","year":"2024","journal-title":"Anticancer Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16564","article-title":"Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-\u03baB activity","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S257052","article-title":"Association of TP53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer","volume":"13","author":"Fang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101767","article-title":"A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study","volume":"54","author":"Liu","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29526","DOI":"10.1038\/s41598-025-10334-1","article-title":"Chidamide and anlotinib synergistically inhibit high grade B-cell lymphomas via PI3K\/AKT signaling pathway","volume":"15","author":"Lin","year":"2025","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.628895","article-title":"Intratumoral injection of anlotinib hydrogel combined with radiotherapy reduces hypoxia in lewis lung carcinoma xenografts: assessment by micro fluorine-18-fluoromisonidazole positron emission tomography\/computed tomography hypoxia imaging","volume":"11","author":"Gao","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO\/CALGP\/ACO- GAIN-trial","volume":"20","author":"Goetze","year":"2020","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1511583","article-title":"Efficacy of neoadjuvant therapy and lymph node dissection in advanced gallbladder cancer without distant metastases: a SEER database analysis","volume":"14","author":"Dong","year":"2024","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2012.00544.x","article-title":"Role of radical surgery in patients with stage IV gallbladder cancer","volume":"14","author":"Kang","year":"2012","journal-title":"HPB (Oxford)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2019.02.015","article-title":"Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review","volume":"219","author":"Kitano","year":"2020","journal-title":"Am J Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-3877-y","article-title":"Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival","volume":"41","author":"Yamada","year":"2017","journal-title":"World J Surg"},{"key":"B36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet (London England)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215257","article-title":"Gallbladder cancer: current insights in genetic alterations and their possible therapeutic implications","volume":"13","author":"Kuipers","year":"2021","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res: An Off J Am Assoc Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1697015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:20:09Z","timestamp":1769412009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1697015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1697015"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1697015","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1697015"}}